Body Distribution of Nanoparticle-Containing Adriamycin Injected into the Hepatic Artery of Hepatoma-Bearing Rats
Tóm tắt
The aim of the study was to investigate the body distribution of nanoparticle-containing adriamycin (NADR) injected into the hepatic artery of hepatoma-bearing rats. Thirty Walker-256 hepatoma-bearing rats were divided into two groups at random, with 15 rats in each. NADR and free adriamycin (FADR) were injected into the hepatic artery of animals on the seventh day after tumor implantation. At 1, 5, and 15 hr, after administration, five animals in each group were sacrificed and the ADR concentrations in the plasma, liver, heart, spleen, lungs, kidneys, and tumor were determined. The results showed that NADR substantially increased the ADR concentrations in liver, spleen, and tumor of rats compared to FADR, whereas the concentrations in plasma, heart, and lungs were significantly decreased. In conclusion, the body distribution of ADR can be modified by its encapsulation into nanoparticles and administration via the hepatic artery.
Tài liệu tham khảo
Rupniak HT, Whelan RDH, Hill BT: Concentration and timedependent inter-relationships for antitumor drug cytotoxicities against tumor cells in vitro. Int J Cancer 32:7–12, 1983
Kim CK, Lim SJ: Recent progress in drug delivery systems for anticancer agents. Arch Pharm Res 25:229–239, 2002
Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P: Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol 26:122–126, 1990
Ridge LA, Collin C, Bading JR, Hancock C, Conti PS, Daly JM, Raaf JH: Increased Adriamycin levels in hepatic implants of rabbits VX2 carcinoma from regional infusion. Cancer Res 48:4584–4587, 1988
Andrieu V, Fessi H, Dubrasquet M, Devissaguet JP, Puisieux F, Benita S: Pharmacokinetic evaluation of indomethacin nanocapsules. Drug Des Deliv 4:295–302, 1989
Zou Y, Ueno M, Yamagishi M, Yamashita I, Horikoshi I, Tazawa K, Gu X: Targeting behavior of hepatic artery injected temperature sensitive liposomal Adriamycin on tumor-bearing rats. Select Cancer Ther 6:119–127, 1990
Zou Y, Horikoshi I, Ueno M, Gu X: The quantitative analysis of Adriamycin in vitro. J S Y C Pharm 9:6–9, 1992
Jordan A: Nanotechnology and consequences for surgical oncology. Kongressbd Dtsch Ges Chir Kongr 119:821–828, 2002
Astier A, Doat B, Ferrer MJ, Benoit G, Fleury J, Rolland A, Leverge R: Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form polymethacrylate nanospheres, in U-937 cells. Cancer Res 48:1835–1841, 1988
Jia L, Wong H, Wang Y, Garza M, Weitman SD: Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci 92:161–172, 2003
Chen JH, Ling R, Yao Q, Wang L, Ma Z, Li Y, Wang Z, Xu H: Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into the hepatic artery. World J Gastroenterol 10:1989–1991, 2004